PATENT CLAIM ANALYSIS

Application Number: 15890847
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "324000"]

Abstract:
The present disclosure relates generally to determining the risk of developing breast cancer. In particular, the present disclosure provides materials and methods for determining whether a subject diagnosed with a non-cancerous breast tumor will develop cancer based on expression of multiple oncogenic biomarkers in the non-cancerous breast tumor. The present disclosure also provides a cancer risk score to determine whether a subject has low risk, intermediate risk, or high risk of developing cancer, thereby permitting selection of appropriate therapies to treat the subject. The present disclosure addresses the need for improved diagnostic assessment of early hyperplastic lesions, the presence of which in a subject is a significant indicator that a subject will eventually develop invasive breast cancer.

Claim (Index 32):
A method of monitoring a patient at risk for cancer, the method comprising:\n quantifying levels of at least two oncogenic biomarkers or fragments thereof from a first hyperplastic tissue sample from a subject; calculating a first risk score based on the levels of the at least two oncogenic biomarkers or fragments thereof from the first hyperplastic tissue sample; determining that the subject has a low, intermediate or high risk of developing cancer based on the calculated risk score; administering to the subject having an intermediate or high risk of developing cancer an anti-cancer agent for a period of time to prevent cancer; obtaining a second hyperplastic or non-hyperplastic tissue sample from the subject; evaluating the change in the levels of the at least two oncogenic biomarkers or fragments thereof from the second hyperplastic or non-hyperplastic tissue sample based on the first hyperplastic tissue sample; calculating a second risk score based on the levels of the at least two oncogenic biomarkers or fragments thereof from the second hyperplastic or non-hyperplastic tissue sample; and comparing the first risk score with the second risk score and determining whether to (i) discontinue use of the anti-cancer agent in the subject; (ii) continue treatment with the anti-cancer agent in the subject; or (iii) administer a different anti-cancer agent to the subject based on the comparison of the first and second risk scores.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 88.0
- Lexical Diversity: 1.85294
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11037889', '13350480', '14537521', '13539102', '15483218']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7633667914835293
- 35 USC 102 Novelty (BERT): 0.5066084129444821
- Combined Prediction Score: 0.7376909536296246
- Mean Citation Score: 229.131988
- Max Citation Score: 233.30148
- Similarity Product: 142.93605394876957

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test